Table of Contents
Last Updated: February 29, 2024
Below is an overview of the sections found in the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.
- Overview of COVID-19
- Testing for SARS-CoV-2 Infection
- Prevention of SARS-CoV-2 Infection
- Clinical Spectrum of SARS-CoV-2 Infection
- Prioritization of Anti-SARS-CoV-2 Therapies for the Treatment of COVID-19 in Nonhospitalized Patients When There Are Logistical Constraints
- Clinical Management of Adults Summary
- General Management of Nonhospitalized Adults With Acute COVID-19
- Therapeutic Management of Nonhospitalized Adults With COVID-19
- Therapeutic Management of Hospitalized Adults With COVID-19
Clinical Management of Children
- Clinical Management of Children Summary
- Special Considerations in Children
- Therapeutic Management of Nonhospitalized Children With COVID-19
- Therapeutic Management of Hospitalized Children With COVID-19
- Therapeutic Management of Hospitalized Children With MIS-C, Plus a Discussion on MIS-A
- Care of Critically Ill Adults With COVID-19 (Summary Recommendations)
- Introduction to Critical Care Management of Adults With COVID-19
- Hemodynamics for Adults
- Oxygenation and Ventilation for Adults
- Pharmacologic Interventions for Critically Ill Patients
- Extracorporeal Membrane Oxygenation for Adults
- Introduction to Critical Care Management of Children With COVID-19
- Hemodynamic Considerations for Children
- Oxygenation and Ventilation for Children
- Extracorporeal Membrane Oxygenation for Children
Antivirals, Including Antibody Products
- Antiviral Agents, Including Antibody Products (Summary Recommendations)
- Remdesivir
- Table 4a. Remdesivir: Selected Clinical Trial Data
- Ritonavir-Boosted Nirmatrelvir (Paxlovid)
- Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications
- Molnupiravir
- Anti-SARS-CoV-2 Monoclonal Antibodies
- Table 4b. Anti-SARS-CoV-2 Monoclonal Antibodies: Selected Clinical Trial Data
- COVID-19 Convalescent Plasma
- Table 4c. COVID-19 Convalescent Plasma: Selected Clinical Trial Data
- Interferons
- Table 4d. Interferons: Selected Clinical Trial Data
- Table 4e. Characteristics of Antiviral Agents, Including Antibody Products
- Immunomodulators (Summary Recommendations)
- Systemic Corticosteroids
- Table 5a. Systemic Corticosteroids: Selected Clinical Trial Data
- Inhaled Corticosteroids
- Table 5b. Inhaled Corticosteroids: Selected Clinical Trial Data
- Interleukin-6 Inhibitors
- Table 5c. Interleukin-6 Inhibitors: Selected Clinical Trial Data
- Janus Kinase Inhibitors
- Table 5d. Janus Kinase Inhibitors: Selected Clinical Trial Data
- Abatacept
- Infliximab
- Interleukin-1 Inhibitors
- Vilobelimab
- Table 5e. Characteristics of Immunomodulators
Antithrombotic Therapy in Patients With COVID-19
- Table 6a. Anticoagulant Therapy: Selected Clinical Trial Data
- Table 6b. Antiplatelet Therapy: Selected Clinical Trial Data
- Miscellaneous Drugs (Summary Recommendations)
- Fluvoxamine
- Table 7a. Fluvoxamine: Selected Clinical Trial Data
- Intravenous Immunoglobulin
- Ivermectin
- Table 7b. Ivermectin: Selected Clinical Trial Data
- Metformin
- Table 7c. Metformin: Selected Clinical Trial Data
- Table 7d. Characteristics of Miscellaneous Drugs
- Supplements (Summary Recommendations)
- Vitamin C
- Vitamin D
- Zinc
Considerations for Using Concomitant Medications in Patients With COVID-19
- Special Considerations in People Who Are Immunocompromised
- Special Considerations in Adults and Children With Cancer
- Special Considerations in Solid Organ Transplant, Hematopoietic Cell Transplant, and Cellular Immunotherapy Candidates, Donors, and Recipients
- Special Considerations During Pregnancy and After Delivery
- Pregnancy, Lactation, and COVID-19 Therapeutics
- Influenza and COVID-19
- Special Considerations in People With HIV
Appendix A, Table 1. COVID-19 Treatment Guidelines Panel Roster